No article notes available at this time.
• Gives residents pooled-evidence numbers to cite when counseling patients on adjuvant chemotherapy after resection of soft-tissue sarcoma, rather than relying on single small trials. • Clarifies that doxorubicin alone has only a marginal, non-significant effect on survival, while adding ifosfamide produces a statistically significant survival benefit — a distinction relevant to regimen selection discussions with medical oncology. • Reinforces that any survival benefit must be weighed against the added toxicity of combination chemotherapy, framing this as a risk-benefit discussion rather than a clear-cut recommendation.
No article notes available at this time.
• Gives residents pooled-evidence numbers to cite when counseling patients on adjuvant chemotherapy after resection of soft-tissue sarcoma, rather than relying on single small trials. • Clarifies that doxorubicin alone has only a marginal, non-significant effect on survival, while adding ifosfamide produces a statistically significant survival benefit — a distinction relevant to regimen selection discussions with medical oncology. • Reinforces that any survival benefit must be weighed against the added toxicity of combination chemotherapy, framing this as a risk-benefit discussion rather than a clear-cut recommendation.